Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-12-02 pm EST
178.88 USD   +0.08%
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”)
PU
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Resisting Steeper Tuesday Market Losses

01/25/2022 | 01:05pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. 0.85% 19.06 Delayed Quote.3.31%
JOHNSON & JOHNSON 0.08% 178.88 Delayed Quote.4.57%
NASDAQ COMPOSITE -0.18% 11461.5 Real-time Quote.-26.74%
All news about JOHNSON & JOHNSON
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
12/01Global markets live: General Electric, Tesla, Apple, Salesforce, Boe..
MS
12/01There are two ways to look at Powell's speech
MS
12/01Morgan Stanley Adjusts Price Target on Johnson & Johnson to $178 From $170, Maintains E..
MT
12/01First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results ..
AQ
12/01Johnson & Johnson : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
11/30J&J CEO Joaquin Duato to take additional role of Chairman
RE
11/30Johnson & Johnson Chief Executive Joaquin Duato to Also Assume Chairman Role
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 035 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 22,0x
Yield 2022 2,43%
Capitalization 468 B 468 B -
EV / Sales 2022 4,81x
EV / Sales 2023 4,59x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 178,88 $
Average target price 181,90 $
Spread / Average Target 1,69%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774
MERCK & CO., INC.43.58%278 995